Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M259Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-0.8EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)25.1Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book4.810-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M5,250,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with PBE

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

PBE is held by these investors:



PBE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.48421.31view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94191.74view
Dinwoodie, Tyler Wayne PaulSenior Officer 2017-01-16Buy4,000$0.1728970.59view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.363533.82view
Bebek, IvanDirector 2017-01-16Buy8,990$3.381362.13view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4111953.66view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.9177.07view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.27688.2view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.38-18.15view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1532846.67view

Quarterly/Annual Reports about PBE:

    News about PBE:

    Articles On GuruFocus.com

    More From Other Websites
    Gene-Editing Could Modify and Cure Disease: CRISPR vs. TALENs Sep 21 2017
    A Shot in the Arm for the UK Life Sciences Industry? Sep 21 2017
    How Did Gilead’s Blockbuster Drug Harvoni Perform in 2Q17? Sep 12 2017
    What’s Ionis Pharmaceuticals’ Valuation? Aug 23 2017
    What Drove Biogen Stock in 2Q17? Jul 10 2017
    How Incyte’s Valuation Has Changed since 1Q17 Results Jun 14 2017
    Changes in Ionis Pharmaceuticals’ Valuation after 1Q17 Jun 09 2017
    Time to Buy Biotech ETF? Mar 13 2017
    Trump's Immigration Plans an Overhang on Biotech ETFs? Mar 02 2017
    A Look at Incyte’s Product Portfolio Mar 01 2017
    What Lies Ahead for Biotech ETFs in Trump Era? Jan 27 2017
    Trump Attacks Biotech & Pharma: ETFs Bleed Jan 12 2017
    What’s in Incyte’s Product Portfolio? Jan 09 2017
    Neurocrine Biosciences Pursues Women’s Health Segment with Elagolix Dec 02 2016
    Biotech ETFs Slumping on Q3 Results Nov 08 2016
    4 Frightful ETFs of This Year Oct 27 2016
    3 ETFs to Buy for a Media Merger Frenzy Oct 05 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat

    {{numOfNotice}}